- Home
- CLNN vs SPRO Comparison
CLNN vs SPRO Comparison
Compare CLNN & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLNN
- SPRO
- Stock Information
- Founded
- CLNN 2012
- SPRO 2013
- Country
- CLNN United States
- SPRO United States
- Employees
- CLNN N/A
- SPRO N/A
- Industry
- CLNN Biotechnology: Pharmaceutical Preparations
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- CLNN Health Care
- SPRO Health Care
- Exchange
- CLNN Nasdaq
- SPRO Nasdaq
- Market Cap
- CLNN 37.7M
- SPRO 45.7M
- IPO Year
- CLNN N/A
- SPRO 2017
- Fundamental
- Price
- CLNN $4.37
- SPRO $0.78
- Analyst Decision
- CLNN Strong Buy
- SPRO Buy
- Analyst Count
- CLNN 4
- SPRO 4
- Target Price
- CLNN $55.25
- SPRO $5.00
- AVG Volume (30 Days)
- CLNN 42.3K
- SPRO 95.8K
- Earning Date
- CLNN 05-07-2025
- SPRO 03-21-2025
- Dividend Yield
- CLNN N/A
- SPRO N/A
- EPS Growth
- CLNN N/A
- SPRO N/A
- EPS
- CLNN N/A
- SPRO 0.06
- Revenue
- CLNN $421,000.00
- SPRO $106,455,000.00
- Revenue This Year
- CLNN N/A
- SPRO N/A
- Revenue Next Year
- CLNN N/A
- SPRO N/A
- P/E Ratio
- CLNN N/A
- SPRO $11.74
- Revenue Growth
- CLNN N/A
- SPRO 37.01
- 52 Week Low
- CLNN $3.82
- SPRO $0.73
- 52 Week High
- CLNN $9.20
- SPRO $1.89
- Technical
- Relative Strength Index (RSI)
- CLNN 45.51
- SPRO 43.97
- Support Level
- CLNN $4.25
- SPRO $0.73
- Resistance Level
- CLNN $4.60
- SPRO $0.80
- Average True Range (ATR)
- CLNN 0.32
- SPRO 0.03
- MACD
- CLNN 0.01
- SPRO 0.00
- Stochastic Oscillator
- CLNN 46.67
- SPRO 46.63
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.